Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer

Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the standard of care for patients in whom tumors are presenting...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lung Cancer (Auckl)
Hlavní autoři: Berghmans, Thierry, Remmelink, Myriam, Awada, Ahmad
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2012
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312487/
https://ncbi.nlm.nih.gov/pubmed/28210128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S12959
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky